business

AbbVie Acquires Apogee for $10.9 Billion to Enhance Inflammatory Disease Portfolio

22 Haziran 2026Financial Times

AbbVie has acquired Apogee for $10.9 billion, marking its largest deal in over five years. This acquisition is part of a broader trend of increased mergers and acquisitions within the pharmaceutical sector.
The focus of the deal is on Apogee's drug for inflammatory diseases, which aligns with AbbVie's strategic goals.
The pharmaceutical sector has seen a notable increase in mergers and acquisitions recently, driven by the need for companies to expand their product offerings and pipeline. AbbVie's purchase of Apogee reflects a strategic response to these industry dynamics, particularly as companies seek to innovate and maintain co…
This acquisition highlights AbbVie's aggressive strategy to bolster its portfolio in the competitive inflammatory disease market. As the pharmaceutical industry experiences a wave of consolidation, AbbVie's move may set the stage for further industry shifts, potentially impacting drug pricing and availability.

NewsAI özeti

This article is for informational purposes only and does not constitute financial advice.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.